Navigation Links
United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
Date:11/5/2009

NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan® (sapropterin dihydrochloride) with food for the treatment of phenylketonuria (PKU). The patent expires in 2024.

"We believe that the food effect patent, based on the discovery that food increases the bioavailability of Kuvan, along with our patents for once daily dosing and stable tablet formulation, will create significant barriers to therapeutically equivalent generic competition from entering the market for approximately ten years beyond orphan drug exclusivity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain committed to serving the PKU community with initiatives such as implementation of an outcomes study in the second quarter of next year and the ongoing development of a blood Phe monitor. We also look forward to results from various investigator-sponsored trials that, if positive, will strengthen the value proposition for the use of Kuvan."

About Kuvan

Kuvan® (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
3. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
7. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
8. Premier Research Expands its Medical Device Operations to the United States
9. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
10. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
11. EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... MELVILLE, N.Y. , April 1, 2015  Henry ... provider of health care products and services to office-based ... completion of its acquisition of scil animal care company ... of animal health laboratory and imaging diagnostic products and ... and Europe.  This transaction was announced on ...
(Date:3/31/2015)... 2015 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... exclusive collaboration and licensing agreement for the development and ... Japan and other select Asian markets with ... to initially develop NBI-98854 in Japan ... tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 ...
(Date:3/31/2015)... , March 31, 2015  The increasing ... applications have driven the need for automated ... automated segments are going to replace the ... This study provides the market overview, market ... key trends for the liquid handling market ...
Breaking Medicine Technology:Henry Schein Completes Acquisition of scil animal care 2Henry Schein Completes Acquisition of scil animal care 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4Western European Liquid Handling Market 2
... YORK, July 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0574348/European-Medical-Displays-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This research ... market in terms of the challenges faced ...
... drug companies face a number of obstacles to commercialize ... (FDA) and GMP compliance, to distribution agreements and the ... must be coordinated.  Those issues have just become easier ... VPCI have entered into a joint association.  The collaboration ...
Cached Medicine Technology:European Medical Displays Markets 2European Medical Displays Markets 3European Medical Displays Markets 4Spanish Drug Companies Have New Support Option for the U.S. Market 2
(Date:4/1/2015)... MEETING, PA (PRWEB) April 01, 2015 ... assistance company and a subsidiary of West Corporation, today ... available at http://blog.healthadvocate.com and through the Health ... help healthcare consumers get, and stay, healthy. , “We’re ... contents available to the public,” said Martin Rosen, Executive ...
(Date:4/1/2015)... 2015 Senior Helpers of Central Texas ... Provider of Choice Award by Home Care Pulse. The Best ... given to home care providers who receive the highest satisfaction ... quality in home care. This recognition reassures you that your ... provide you with quality, trustworthy in home care. , In ...
(Date:4/1/2015)... York (PRWEB) April 01, 2015 On May ... will host its annual Educational Institute in Albany, New ... innovations, and initiatives in nursing and feature an address by ... Jean M. Hill Professor, University of Kansas School of Nursing ... The event is being sponsored by the Excelsior College School ...
(Date:4/1/2015)... 2015 Franklin University, one of the ... the establishment of the Greta J. Russell Medical Mutual ... through the generous gift of $100,000 from Medical Mutual ... of Medical Mutual to University representatives, Dr. David ... Advancement & Strategic Relations. , “We are grateful ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 ScooterDirect.com is ... mobility scooters to improve their customers’ lifestyle using electric ... to the special needs of the people, they provide ... people to become independent and enjoy their freedom. Scooterdirect.com ... Scooter at discounted prices. , One of ...
Breaking Medicine News(10 mins):Health News:Health Advocate Launches New Health and Wellness Blog 2Health News:Senior Helpers of Central Texas Awarded Prestigious 2015 Senior Home Care Provider of Choice Award from Home Care Pulse 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 3Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 3Health News:ScooterDirect.com Offering Pride Go Go Traveller Elite 3 Wheel Scooter 2
... Self-Funding Healthcare Conference and Expo will provide employers and ... options during a June 1-3, 2009 conference in Kansas ... an employer rather than a conference promoter. ... the event to help educate employers and plan sponsors ...
... of imaging techniques, the accuracy of preoperative rectal cancer ... function in rectal cancer patients has become a very ... to be published on March 14, 2009 in the ... factors for 5-year survival after local excision of rectal ...
... typical backgrounds of the patients are diagnosed by radiological ... diagnostic imaging techniques. A typical LCA shows low density ... contrasting effect on arterial phase and does not show ... LCA in magnetic resonance imaging shows almost the same ...
... with atrial fibrillation. In the current edition of ... 164-70), Thomas Bitter and his coauthors from the Ruhr ... in this form of cardiac arrythmia and what the ... polygraphy to investigate whether 150 patients (110 men and ...
... Balance SheetATLANTA, March 20 In a time when ... healthcare centers are finding themselves in the same position ... of available financing is putting a damper on major ... the world,s leading manufacturers of oncology and neurosurgical devices ...
... March 20 Boehringer Ingelheim today announced that ... Phase III Randomized Evaluation of Long term Anticoagulant ... efficacy and safety of the oral direct thrombin ... warfarin (target international normalized ratio, INR, 2-3) for ...
Cached Medicine News:Health News:Deffenbaugh Industries to Host Self-Funding Healthcare Conference in Kansas City 2Health News:Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases 2Health News:Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 4
... insertion of Alcon Acrylic, Chiron/Iolab LI-41 and Pharmacia ... are taller and thinner, maximizing the surface area ... migration during loading and insertion, and makes it ... folded lens optic. The special direct-acting jaws release ...
Autoref / Ker N vision K 5001 has auto fogging, wide view window, near vision reading. Clear 5.6 Inch color monitor. Data screen function. SE Value display function. Quick printer with automatic cutt...
KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....
... the child-friendly, portable autorefractor that tests ... It can perform objective refraction from ... away even through glasses and contact ... sounds engage the patient throughout the ...
Medicine Products: